Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 3,808.3% in July

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 46,900 shares, a growth of 3,808.3% from the July 15th total of 1,200 shares. Based on an average trading volume of 82,100 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.5% of the company’s shares are sold short.

Artelo Biosciences Stock Performance

ARTL opened at $1.30 on Wednesday. The stock has a market capitalization of $4.20 million, a PE ratio of -0.41 and a beta of 1.43. The stock’s 50 day moving average price is $1.33 and its 200-day moving average price is $1.41. Artelo Biosciences has a 52-week low of $1.15 and a 52-week high of $2.98.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.27. Research analysts forecast that Artelo Biosciences will post -2.09 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Artelo Biosciences in a research note on Wednesday, June 5th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.